Metastatic Penile Cancer: What to Ask

Penile cancer is staged with the AJCC TNM system. Stage IV is not one thing. The 8th edition assigns it to any of three combinations.

• T4, any N, M0. T4 means the tumor has grown into nearby structures. Those are the scrotum, the prostate, or the pubic bone.
• Any T, N3, M0. Clinical N3 means a fixed mass of inguinal (groin) nodes that can be felt, or swollen pelvic nodes, on one side or both. Pathological N3 means cancer growing out through the node capsule, or spread to pelvic lymph nodes.
• Any T, any N, M1. M1 means distant spread.

Those three are treated differently. A fixed groin mass with no distant spread is a local-control problem. Spread to lung or bone is a whole-body problem. So the first question here is which of the three descriptions applies.

NCI's health-professional summary does not soften this. No standard treatment exists that cures stage IV penile cancer. Therapy is directed at palliation.

That word carries a specific meaning here, not a vague one. Palliation in stage IV penile cancer is achieved with surgery or with radiation therapy. The goals are named.

• Palliative surgery may be used to control the penile lesion itself. It is also used to prevent the tissue death, infection, and bleeding that untreated groin nodes can cause.
• Radiation therapy may be palliative for the primary tumor, for groin and pelvic nodes, and for spread to bone.

Preventing a groin node from breaking through the skin is a concrete surgical goal. It is worth naming out loud in a planning conversation.

Earlier stages read differently. NCI's patient summary says penile cancer is highly curable when found early. The health-professional summary sets no cure expectation at stage IV at all. That contrast is why the shape of the conversation changes here.

The PDQ names four chemotherapy drugs with some efficacy in stage IV penile cancer. They are vincristine, cisplatin, methotrexate, and bleomycin. The combination of vincristine, bleomycin, and methotrexate has been effective two ways. It has worked as adjuvant therapy, meaning after surgery, and as neoadjuvant therapy, meaning before it.

In stage III disease, two more data points are on record. Neoadjuvant full-dose cisplatin plus continuous-infusion fluorouracil has been effective. And lower-dose cisplatin on its own was tested in a large trial and was ineffective. That is a useful reminder that the drug name alone is not a plan.

Clinical trials combining chemotherapy with palliative local control are described as appropriate at this stage.

If fluorouracil or capecitabine is on the table, one pharmacogenetic question matters more than most.

The DPYD gene codes for the enzyme that breaks down fluoropyrimidines. Fluorouracil and capecitabine are both fluoropyrimidines. An estimated 1% to 2% of people carry inherited DPYD variants that weaken that enzyme, so the drug builds up. People with the DPYD*2A variant who receive these drugs may have severe, life-threatening toxicity that is sometimes fatal. Many other DPYD variants exist, with a range of effects.

The advice depends on the genotype, and on how many working DPYD alleles a person has. It may be to avoid these drugs entirely, or to cut the dose by 50%.

The PDQ is candid about the trade-offs. DPYD genetic testing costs less than $200. But insurance coverage varies, because national guidelines are lacking. Testing can also delay therapy by about 2 weeks, which the summary says would not be advisable in urgent situations. It calls the issue controversial and in need of further study. That is exactly the kind of decision worth raising rather than assuming.

For 2026 the American Cancer Society estimates about 2,260 new penile cancers in the United States and about 450 deaths. The PDQ has not caught up: it still prints the 2025 pair, 2,190 new cases and 510 deaths, for the wider category of penile and other male genital cancer. NCI's own text adds that the rate is under 1 per 100,000 men per year.

The PDQ states the consequence directly. Because the cancer is so rare in the United States, trials built only for penile cancer are infrequent. People with stage III and stage IV disease are described as candidates for phase I and phase II trials. Those trials test new drugs, biological therapy, or surgical techniques, aimed at better local control and control of distant spread.

Pathology is worth confirming too. Virtually all penile carcinomas are squamous cell. Recognized subtypes include verrucous, warty (also called verruciform), and basaloid. Warty and basaloid carcinoma appear more strongly tied to human papillomavirus, particularly HPV 16, than typical squamous cell or verrucous carcinoma is. Neuroendocrine carcinoma of the penis also occurs. That is a different disease, with different treatment.

• Which stage IV definition applies here — T4 growth into nearby structures, N3 nodes, or M1 distant spread?
• Is the goal local control, systemic control, symptom relief, or a combination?
• For fixed groin nodes: what is the plan to prevent skin breakdown, bleeding, or infection?
• Which chemotherapy drugs are proposed, in what combination, and at what doses?
• If fluorouracil or capecitabine is planned, will DPYD testing be done first? What does it cost here, and would waiting 2 weeks for the result be safe?
• What is the exact histologic subtype on the pathology report, and is it HPV-related?
• Is neuroendocrine carcinoma excluded?
• Are there phase I or phase II trials open, here or elsewhere, and does eligibility depend on treatment given first?
• Given how few of these cancers any one center sees, would review at a high-volume center or a tumor board change the plan?

Two related pages cover neighboring ground. Penile cancer recurrence, what to ask covers disease that returns after treatment. Cancer staging explains how TNM works in general. And palliative care covers the symptom-focused specialty, which can run alongside cancer treatment rather than replacing it.

This page is a planning aid built from NCI's published summaries. It is not a prediction. It cannot substitute for a clinician who has read the full record.

• Call 911 or go to an emergency department if bleeding from the penile lesion or from a groin mass does not stop after a few minutes of firm pressure. Untreated groin nodes can erode into skin and vessels, which is one reason the PDQ names bleeding as something palliative surgery is used to prevent. If you are on chemotherapy, a temperature of 100.4°F (38°C) or higher belongs in this bullet too: cisplatin, methotrexate and fluorouracil all knock your white cells back, and CDC classes a fever during chemotherapy as a medical emergency. Be seen straight away rather than phoning and waiting.
• Call your care team the same day if the skin over a groin lump breaks down, weeps, smells foul, or the area turns red and spreads, especially with a temperature of 100.4°F (38°C) or higher and you are not on chemotherapy. Also call the same day if you are taking fluorouracil or capecitabine and get heavy diarrhea, mouth ulcers that stop you eating, or sores on your hands and feet. Those are the toxicities a DPYD variant amplifies.
• Call your care team within a day or two if a groin lump is visibly growing, one leg swells, or pain in the groin or pelvis is climbing week on week. These change what local control can still achieve, and waiting narrows the options.

• NCI PDQ — Penile Cancer Treatment, health professional version
• NCI PDQ — Penile Cancer Treatment, patient version
• NCI — Bleeding and Bruising (Thrombocytopenia) During Cancer Treatment
• NCI — Infection and Neutropenia During Cancer Treatment
• CDC — Watch Out for Fever (Preventing Infections in Cancer Patients)
• American Cancer Society — key statistics for penile cancer